Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Shell Companies

Financial Services
$10.90 +0.00%

+$0.00 today

Market cap
$264.62M
Beta
0.00
P/E (TTM)
36.7
EPS (TTM)
$0.29
52W Low $10.17High $10.63

Volume 0.00M

Average 0.11M

DMAA Total Current Assets

All assets expected to be converted to cash or used up within one year.

Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets falls 79.0% from a year ago

Total current assets stood at $14.89K at the end of Q1 FY2026, down 79.0% from a year earlier and up 22.1% from the prior quarter.

Context

  • Total current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.

What to watch

Whether total current assets keeps falling in the next quarterly balance sheet after a -79.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.89K+22.1% QoQ
Last fiscal yearDec 2025
$12.19K+144.3% YoY
Year agoMar 2025
$71.02K-79.0% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-79.0%——
1 year+144.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
12.19K USD
Year-over-year change
+144.3%
1-year CAGR
+144.3%

Total Current Assets vs competitors

How DMAA compares with its peers on the latest reported figures

  • DMAA's Mar 2026 total current assets of $14.89K is the lowest of the 10 companies compared; the peer median is $405.16K.
  • Its year-over-year change of -79.0% is the 7th highest of 9, against a peer median of -23.8%.
  • Total current assets amounts to 0.0% of total assets for DMAA, versus a peer median of 0.1%.
DMAA Competitors Peer median
Total Current Assets for DMAA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LOKVLive Oak Acquisition Corp. V Class A Ordinary SharesMar 2026$1.21M -50.4%—0.5%
OYSEOyster Enterprises II Acquisition CorpMar 2026$888.17K ——0.3%
TACHTitan Acquisition Corp.Mar 2026$613.06K +2453820.7%—0.2%
SIMASIM Acquisition Corp. IMar 2026$607.15K +2.9%—0.2%
TACOUBerto Acquisition Corp. UnitMar 2026$405.16K +3575.6%—0.1%
TACOBerto Acquisition Corp.Mar 2026$405.16K +3575.6%—0.1%
RTACRenatus Tactical Acquisition Corp I Class A Ordinary SharesMar 2026$343.83K -72.1%—0.1%
MLACMountain Lake Acquisition Corp.Mar 2026$216.31K -83.7%+69.6%0.1%
ALFCenturion Acquisition Corp.Mar 2026$54.53K -92.0%—0.0%
DMAADrugs Made In America Acquisition Corp. Ordinary SharesMar 2026$14.89K -79.0%—0.0%
Peer median (excluding DMAA) $405.16K-23.8%+69.6%0.1%

Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.